- Home
- SAIA vs AXSM Comparison
SAIA vs AXSM Comparison
Compare SAIA & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAIA | AXSM |
|---|---|---|
| Founded | 1924 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.0B |
| IPO Year | 2002 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SAIA | AXSM |
|---|---|---|
| Price | $331.26 | $156.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 17 |
| Target Price | ★ $378.56 | $210.65 |
| AVG Volume (30 Days) | ★ 553.5K | 479.1K |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 9.52 | N/A |
| Revenue | ★ $3,234,286,000.00 | N/A |
| Revenue This Year | $6.30 | $58.18 |
| Revenue Next Year | $9.37 | $55.45 |
| P/E Ratio | $35.10 | ★ N/A |
| Revenue Growth | ★ 0.79 | N/A |
| 52 Week Low | $248.37 | $86.99 |
| 52 Week High | $430.11 | $191.50 |
Technical Indicators
Market Signals| Indicator | SAIA | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 40.92 |
| Support Level | $316.05 | $150.75 |
| Resistance Level | $364.86 | $169.11 |
| Average True Range (ATR) | 14.24 | 4.57 |
| MACD | 0.05 | 0.69 |
| Stochastic Oscillator | 33.49 | 28.11 |
Price Performance
Historical ComparisonAbout SAIA Saia Inc.
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.